Publication date: Jul 08, 2019
Currently, few disease-modifying therapies exist for degenerative movement disorders. Antisense oligonucleotides are small DNA oligonucleotides, usually encompassing ∼20 base pairs, that can potentially target any messenger RNA of interest. Antisense oligonucleotides often contain modifications to the phosphate backbone, the sugar moiety, and the nucleotide base. The development of antisense oligonucleotide therapies spinal muscular atrophy and Duchenne muscular dystrophy suggest potentially wide-ranging therapeutic applications for antisense oligonucleotides in neurology. Successes with these two diseases have heightened interest in academia and the pharmaceutical industry to develop antisense oligonucleotides for several movement disorders, including, spinocerebellar ataxias, Huntington’s disease, and Parkinson’s disease. Compared to small molecules, antisense oligonucleotide-based therapies have an advantage because the target disease gene sequence is the immediate path to identifying the therapeutically effective complementary antisense oligonucleotide. In this review we describe the different types of antisense oligonucleotide chemistries and their potential use for the treatment of human movement disorders. © 2019 International Parkinson and Movement Disorder Society.
Scoles and Pulst, S.M. Antisense therapies for movement disorders. 06569. 2019 Mov Disord.
|disease||MESH||spinal muscular atrophy|
|disease||DOID||Duchenne muscular dystrophy|
|disease||MESH||Duchenne muscular dystrophy|
|disease||DOID||spinal muscular atrophy|
- Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington’s Disease.
- Biotech Braces for Busy Summer as 2019 M&A Volume Heats Up
- Orphan Drugs – Proactive Initiatives Undertaken By Government And Regulatory Authorities
- Recent advances in molecular therapies for neurological disease: triplet repeat disorders.
- Experimental Huntington’s disease drug can be given less frequently